Teleflex (TFX) Resumen de Acciones
Teleflex Incorporated diseña, desarrolla, fabrica y suministra dispositivos médicos de un solo uso para procedimientos diagnósticos y terapéuticos comunes en cuidados críticos y aplicaciones quirúrgicas en Estados Unidos, Europa, Oriente Medio, África, Asia-Pacífico e internacionalmente. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 3/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 1/6 |
| Dividendos | 2/6 |
Recompensas
Análisis de riesgos
TFX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Teleflex Incorporated
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$134.04 |
| Máximo en las últimas 52 semanas | US$139.67 |
| Mínimo de 52 semanas | US$100.18 |
| Beta | 0.82 |
| Cambio en 1 mes | -1.26% |
| Variación en 3 meses | 13.22% |
| Cambio de 1 año | 11.76% |
| Variación en 3 años | -45.75% |
| Variación en 5 años | -64.37% |
| Variación desde la OPV | 35,679.11% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 07
TFX: Biotronik Synergies And Portfolio Separation Will Reshape Earnings Profile
Analysts have lifted their fair value estimate for Teleflex stock from $155 to $160 as they factor in potential benefits from Biotronik-related synergies, capital deployment that is still filtering into Street models, and possible value creation linked to activist involvement. Analyst Commentary Recent research updates around Teleflex highlight a more constructive tone from bullish analysts, with several price target revisions and rating changes aligning around the new US$160 fair value estimate.
Actualización de narrativa • Jun 22
TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward
Analysts have raised the fair value estimate for Teleflex stock from $116.81 to $135.00, reflecting updated assumptions around capital deployment, Biotronik-related synergies, potential activist-driven value creation, and a slightly higher future P/E multiple. Analyst Commentary Recent Street research on Teleflex has focused on how potential Biotronik synergies, capital deployment plans, and possible activist involvement could influence the stock's risk and reward profile.Artículo de análisis • Jun 19
Teleflex (TFX) Stock Could Be 11.6% Undervalued After Q1 Revenue Beat
Teleflex stock reaction centered on earnings, not new debt issue Teleflex (TFX) has been drawing attention after Q1 revenue topped analyst expectations and investors responded positively, even as the company issued new senior notes and reiterated full year EPS guidance below prior estimates. The recent share price move appears more closely linked to Teleflex's earnings update, where revenue performance and progress on its transformation plan supported sentiment, rather than to the sizeable...Recent updates
Actualización de narrativa • Jul 07
TFX: Biotronik Synergies And Portfolio Separation Will Reshape Earnings Profile
Analysts have lifted their fair value estimate for Teleflex stock from $155 to $160 as they factor in potential benefits from Biotronik-related synergies, capital deployment that is still filtering into Street models, and possible value creation linked to activist involvement. Analyst Commentary Recent research updates around Teleflex highlight a more constructive tone from bullish analysts, with several price target revisions and rating changes aligning around the new US$160 fair value estimate.Actualización de narrativa • Jun 22
TFX: Biotronik Synergies And Activist Pressure Will Shape Execution Risk Going Forward
Analysts have raised the fair value estimate for Teleflex stock from $116.81 to $135.00, reflecting updated assumptions around capital deployment, Biotronik-related synergies, potential activist-driven value creation, and a slightly higher future P/E multiple. Analyst Commentary Recent Street research on Teleflex has focused on how potential Biotronik synergies, capital deployment plans, and possible activist involvement could influence the stock's risk and reward profile.Artículo de análisis • Jun 19
Teleflex (TFX) Stock Could Be 11.6% Undervalued After Q1 Revenue Beat
Teleflex stock reaction centered on earnings, not new debt issue Teleflex (TFX) has been drawing attention after Q1 revenue topped analyst expectations and investors responded positively, even as the company issued new senior notes and reiterated full year EPS guidance below prior estimates. The recent share price move appears more closely linked to Teleflex's earnings update, where revenue performance and progress on its transformation plan supported sentiment, rather than to the sizeable...
Actualización de narrativa • Jun 06
TFX: Portfolio Reset And Recent Upgrades Will Shape Balanced Forward Outlook
Analysts have raised their fair value estimate for Teleflex from $129.25 to about $143.67, citing a lower required discount rate, an updated view on revenue growth and margins, and a higher assumed future P/E multiple following several recent upgrades and target increases from major firms. Analyst Commentary Recent Street research on Teleflex has leaned constructive, with several firms updating ratings and price targets in quick succession.Actualización de narrativa • May 23
TFX: Business Separation And Portfolio Shift Will Drive Future Earnings Repricing
Narrative Update on Teleflex The updated analyst price target for Teleflex moves to $155 from $147, with analysts citing recent upgrades and price target increases, along with the company's ongoing business separation and portfolio optimization efforts, as key supports for the higher fair value and slightly adjusted discount rate and P/E assumptions. Analyst Commentary Recent street research around Teleflex has leaned positive, with several bullish analysts updating views in quick succession.Actualización de narrativa • May 02
TFX: Business Separation And Portfolio Focus Will Reshape Future Earnings Profile
Analysts have reduced their fair value estimate for Teleflex to $147 from $155, citing updated assumptions for revenue growth, profit margins, and future P/E multiples following recent upgrades and price target increases from several research firms. Analyst Commentary Recent research has skewed more optimistic on Teleflex, with several bullish analysts updating their views following the company’s Q4 results, guidance, and plans for a major business transformation.Actualización de narrativa • Apr 17
TFX: Business Separation Execution And Activist Pressure Will Constrain Forward Upside
Teleflex's analyst price target is now framed slightly higher, moving from about $115 to roughly $117. Analysts are factoring in updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E following recent upgrades and price target increases tied to the company's ongoing business separation and portfolio optimization efforts.Actualización de narrativa • Apr 03
TFX: Business Separation And Activist Pressure Will Shape Balanced Forward Outlook
Analysts have raised their average price target for Teleflex to $125 from $115. They cite the company’s ongoing business separation, portfolio optimization, and preparation for future value-creating opportunities as key reasons for the change.Actualización de narrativa • Mar 20
TFX: Business Separation And Leadership Changes Will Shape Balanced Forward Outlook
Narrative update Analysts have raised the Teleflex price target by $10, to $125 from $115, citing the company's business separation efforts, portfolio optimization, and positioning for future value creating opportunities following recent results and guidance. Analyst Commentary Recent research highlights a mixed backdrop for Teleflex, with some firms adjusting targets higher while others stay guarded.Actualización de narrativa • Mar 06
TFX: Business Separation And Portfolio Optimization Will Drive Future Earnings Quality
Narrative Update on Teleflex The analyst price target on Teleflex has shifted toward $125, with analysts pointing to the company’s ongoing business separation, portfolio optimization, and positioning for future value-creating opportunities as key factors behind the revised outlook. Analyst Commentary Bullish analysts are pointing to recent price target moves and rating actions as signals of growing confidence in Teleflex’s ability to execute on its transformation plan and to support higher valuation levels over time.Actualización de narrativa • Feb 20
TFX: Higher Margin Assumptions And CEO Transition Will Shape Bullish Outlook
Narrative Update on Teleflex The updated analyst price target on Teleflex has shifted by $23, with analysts citing refreshed views on long term profit margins and a slightly higher assumed future P/E multiple as key drivers behind the change. Analyst Commentary Recent Street research on Teleflex reflects a mix of optimism about the company’s long term potential and caution around valuation and execution, which helps explain the updated price target.Actualización de narrativa • Feb 06
TFX: CEO Transition And Refined Assumptions Will Shape Bullish Future Outlook
Analysts have adjusted their price targets on Teleflex by aligning fair value estimates to about $129.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions highlighted in recent research, including a Wells Fargo target cut and a Needham upgrade.Actualización de narrativa • Jan 23
TFX: Leadership Transition And Softer Demand Will Shape Steady Forward Outlook
Analysts kept their Teleflex fair value estimate steady at US$115.00, as slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E led them to view the prior price target as still appropriate. What's in the News Board member Stuart Randle has been appointed Interim President and CEO effective January 8, 2026, replacing Liam Kelly.Actualización de narrativa • Jan 09
TFX: Softer Demand And Leadership Change Will Shape Balanced Outlook
Analysts have reduced their price target on Teleflex from US$120.00 to US$115.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News Teleflex issued preliminary 2025 revenue guidance of US$3.270b to US$3.278b, below its prior outlook of US$3.305b to US$3.320b, citing softer demand for intra aortic balloon pumps and catheters in the U.S. and Asia, delays in OEM purchase orders, and lower order volumes across parts of its portfolio (Key Developments).Actualización de narrativa • Dec 20
TFX: Margin Expansion Will Drive Stronger Earnings Despite Revenue Headwinds
Analysts have raised their price target on Teleflex from 152.80 dollars to 155.00 dollars, reflecting expectations for meaningfully higher profit margins that more than offset slightly slower projected revenue growth and a lower future earnings multiple. What's in the News Teleflex narrowed its full year 2025 GAAP revenue growth outlook to 9.10% to 9.60%, and now expects revenue between 3,325 million dollars and 3,340 million dollars.Seeking Alpha • Dec 10
Teleflex: Selling, But How Much?
Summary Teleflex Incorporated rebounded from lows after announcing a $2.03B divestiture of Acute Care, Interventional Urology, and OEM businesses. TFX will use $1B of net proceeds for share buybacks, reducing pro forma net debt to $1.5B, but revenue impact remains ambiguous. Shares now trade at 10x adjusted earnings, with market reaction positive despite uncertainty around divested revenue figures. I maintain a cautious long position, closely monitoring Q4 results to clarify divestment implications and future margin trajectory. Read the full article on Seeking AlphaActualización de narrativa • Dec 06
TFX: Diabetes Trial And Goodwill Charge Will Shape Balanced Future Outlook
Analysts have modestly adjusted their price target on Teleflex, keeping fair value steady at approximately $124.14 per share while refining assumptions for a slightly lower discount rate and marginally improved long term valuation metrics. This reflects incremental confidence in the company’s earnings durability.Actualización de narrativa • Nov 22
TFX: Future Diabetes Trial Progress Will Drive Upside Despite Margin Pressures
Teleflex's analyst price target has been revised downward by $3.57 to $124.14. Analysts cite modest reductions in expected profit margins and growth as driving factors for the update.Artículo de análisis • Nov 09
Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...Actualización de narrativa • Nov 07
TFX: Future Advances In Diabetes Trials And Asian Market Expansion Will Drive Upside
Analysts have revised their price target for Teleflex downward from $132.63 to $127.71. They cite higher discount rates and softer revenue growth projections, despite improved profit margins and a lower expected future price-to-earnings ratio.Artículo de análisis • Oct 30
Teleflex Incorporated (NYSE:TFX) Not Lagging Market On Growth Or Pricing
Teleflex Incorporated's ( NYSE:TFX ) price-to-earnings (or "P/E") ratio of 29.5x might make it look like a strong sell...Artículo de análisis • Sep 11
These 4 Measures Indicate That Teleflex (NYSE:TFX) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Actualización de narrativa • Aug 29
Acquisitions And Asian Expansion Will Broaden Healthcare Horizons
Despite a near-term upside from strong Q2 results, Teleflex’s consensus price target has been revised down to $132.62 due to persistently modest organic growth and muted EPS increases, with valuation already reflecting current expectations despite anticipated second-half acceleration. Analyst Commentary Strong Q2 results provided near-term upside surprise.Artículo de análisis • Aug 04
Results: Teleflex Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates
Last week saw the newest quarterly earnings release from Teleflex Incorporated ( NYSE:TFX ), an important milestone in...Artículo de análisis • Aug 03
Teleflex (NYSE:TFX) Has Announced A Dividend Of $0.34
Teleflex Incorporated ( NYSE:TFX ) has announced that it will pay a dividend of $0.34 per share on the 15th of...Seeking Alpha • Mar 02
Teleflex's Bold Transformation: Why I'm Skeptical On Value Creation
Summary Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player. Splitting the business into RemainCo and NewCo makes strategic sense, but NewCo may struggle with growth and margin leverage as a smaller entity. Even with conservative modeling and valuation assumptions, Teleflex stock looks undervalued by more than 20%, but it's tough to recommend a stock where I have serious doubts about execution and strategy. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Teleflex Incorporated: Compelling Only On One Metric
Summary Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest price-to-sales ratio in a decade. Have the shares fallen into the 'buy zone'? An analysis of Teleflex Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaRentabilidad de los accionistas
| TFX | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 0.04% | -1.5% | 0.6% |
| 1Y | 11.8% | -19.9% | 19.5% |
Rentabilidad vs. Industria: TFX superó a la industria US Medical Equipment, que obtuvo un rendimiento del -19.9% el año pasado.
Rentabilidad vs. Mercado: TFX obtuvo unos resultados inferiores a los del mercado US, que fueron del 19.5% el año pasado.
Volatilidad de los precios
| TFX volatility | |
|---|---|
| TFX Average Weekly Movement | 6.0% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: TFX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de TFX (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1943 | 15,500 | Jason Weidman | www.teleflex.com |
Teleflex Incorporated diseña, desarrolla, fabrica y suministra dispositivos médicos de un solo uso para procedimientos diagnósticos y terapéuticos comunes en cuidados críticos y aplicaciones quirúrgicas en Estados Unidos, Europa, Oriente Medio, África, Asia-Pacífico e internacionalmente. La empresa ofrece productos de medicina vascular y de urgencias que comprenden catéteres de la marca Arrow, sistemas de navegación de catéteres y posicionamiento de puntas, y sistemas de acceso óseo intraóseo para la administración de terapias intravenosas, medición de la presión arterial y recogida de muestras de sangre; sistemas de acceso intraóseo que consisten en sistemas de acceso vascular intraóseo EZ-IO, y sistemas de infusión intraósea esternal Arrow FAST1; y productos hemostáticos, incluidos hemostáticos externos y productos de trauma bajo la marca QuikClot. También ofrece productos intervencionistas, como catéteres coronarios, dispositivos de soporte cardíaco estructural y plataformas de productos de intervención periférica; catéteres GuideLiner, Turnpike y TrapLiner; dispositivos de cierre vascular MANTA y sistemas de biopsia ósea con motor Arrow OnControl; y dispositivos médicos coronarios y periféricos, como globos recubiertos de fármacos, stents y catéteres de balón.
Resumen de fundamentos de Teleflex Incorporated
| Estadísticas fundamentales de TFX | |
|---|---|
| Capitalización bursátil | US$5.77b |
| Beneficios(TTM) | US$1.36m |
| Ingresos (TTM) | US$2.13b |
4,370x
Ratio precio-beneficio (PE)2.8x
Ratio precio-ventas (PS)¿Está TFX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de TFX | |
|---|---|
| Ingresos | US$2.13b |
| Coste de los ingresos | US$949.97m |
| Beneficio bruto | US$1.18b |
| Otros gastos | US$1.18b |
| Beneficios | US$1.36m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.031 |
| Margen bruto | 55.33% |
| Margen de beneficio neto | 0.064% |
| Ratio deuda/patrimonio | 86.6% |
¿Cómo se ha desempeñado TFX a largo plazo?
Ver rendimiento histórico y comparativaDividendos
1.0%
Rentabilidad actual por dividendo4,431%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/09 07:18 |
| Precio de las acciones al final del día | 2026/07/09 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Teleflex Incorporated está cubierta por 25 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Matthew Taylor | Barclays |
| Travis Steed | BofA Global Research |
| James Lucas | Brean Capital Historical (Janney Montgomery) |